Acro Biomedical Co., Ltd.
ACBM
Other OTC0.03
USD
- -
- -
CIK
0001622996
ISIN
US0048921052
CUSIP
004892105
Return %
Stock
S&P500
1Y
3,614.29
26.53
3Y
-98.97
76.60
5Y
-98.84
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Yu-Ting Su
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12175 Visionary Way Fishers IN United States of America 46038
- IPO Date
- Jan 8, 2021
- CIK
- 0001622996
- Website
- acrobiomedicalco.com
- Similar Companies
- Business
- Acro Biomedical Co., Ltd. develops, manufactures, and markets advanced biomaterial-based medical devices primarily focused on regenerative medicine and tissue engineering. The company’s core product portfolio includes ABCcolla® Collagen Matrix, ABCcolla® Bone Graft, ABCcolla® Collagen Acellular Dermal Matrix (ADM) Scaffold, ABCcolla® Collagen Ophthalmic Matrix, and ACROTERM™ Scaffolds and Powders. These medical devices leverage proprietary supercritical CO₂ extraction technology to produce natural collagen scaffolds used in wound care, orthopedics, dentistry, ophthalmology, aesthetic microsurgery, cardiovascular, and neural surgery. Key products such as the ABCcolla® Bone Graft and Bone Matrix promote bone regeneration and repair, while the Collagen Ophthalmic Matrix offers an alternative to donor corneas for transplantation. The company also offers specialized skin care and eye care product lines under the ABCcolla® brand. In the last 1-2 years, Acro Biomedical has achieved several regulatory approvals, including the Taiwan Ministry of Health and Welfare's clearance of its Collagen Ophthalmic Matrix and three Class III regenerative medical devices. These approvals support its ongoing clinical trials and commercial expansion in regenerative medicine, especially in corneal tissue repair. The company’s innovative use of supercritical CO₂ technology to preserve collagen scaffolds has been highlighted internationally, and it has received multiple national innovation awards. Acro Biomedical has also established strategic partnerships to extend rights for its biocompatible artificial cornea product in key markets including Australia. The company reported record growth in 2024 and aims to expand further internationally, fostering collaborations with major medical and research centers in Taiwan and internationally. Founded in 2014 and headquartered in Taiwan, Acro Biomedical operates primarily in the biomaterials and regenerative medicine industry with a focus on human tissue repair applications. Its target customers are medical institutions, surgical centers, and OEM partners in Asia and global markets. The company’s product development is strongly supported by collaborations with Taiwan’s top scientific research institutions and medical centers. Acro Biomedical combines proprietary biotechnology, regulatory achievements, and clinical validation to position itself as a leader in high-end regenerative medical devices. Its latest advances aim to address critical shortages in tissue repair materials, including alternatives to human-donated corneas for transplantation. Overall, Acro Biomedical presents a comprehensive portfolio of collagen-based regenerative medical devices with recent regulatory milestones and strategic expansions enhancing its footprint in the tissue engineering and regenerative medicine markets worldwide.